Context Therapeutics Announces New Chief Medical Officer
Context Therapeutics Inc. (NASDAQ: CNTX), a pioneering biopharmaceutical company dedicated to advancing innovative therapies for solid tumors, has shared significant news regarding its leadership team. The company proudly announces the appointment of Dr. Karen Chagin, M.D. as the new Chief Medical Officer (CMO), effective immediately. Dr. Chagin will step into this role on June 9, following the interim leadership of Dr. Karen Smith, who will continue contributing as a valued member of the Board of Directors.
Dr. Karen Chagin's Expertise in T Cell Therapies
With over ten years of extensive experience in clinical development and regulatory strategies focused on T cell therapies, Dr. Chagin is joining Context at a crucial juncture in its growth. Her background includes previous leadership roles at renowned companies such as Adaptimmune Therapeutics and Tmunity Therapeutics. At Adaptimmune, she significantly influenced the development and successful approval of Tecelra (afamitresgene autoleucel), marking a landmark achievement as the first engineered cell therapy authorized for a solid tumor in the U.S.
Leadership Experience and Credentials
Before her role as Senior Vice President at Adaptimmune, Dr. Chagin held positions that culminated in her becoming the CMO at Tmunity, and subsequently, after Tmunity’s acquisition by Kite Pharma, she led Kite’s operations in Philadelphia. Her earlier career was also enriched with vital clinical development positions at Adaptimmune, Janssen, and GSK. Dr. Chagin holds a B.A. from the University of Pennsylvania and earned her M.D. from Temple University School of Medicine, complemented by a residency at Chicago’s Children’s Memorial Hospital and a fellowship in pediatric hematology and oncology.
Context's Vision and Future Plans
Martin Lehr, the CEO of Context Therapeutics, expressed enthusiasm about Dr. Chagin’s appointment, stating, "Her extensive expertise in developing advanced T cell therapies and leading multifaceted clinical teams makes her an ideal match for Context at this pivotal moment in our journey. Her history of guiding programs from conception to approval is invaluable as we strive to expand our portfolio of T cell engaging bispecific therapeutics. We’re excited to have her join us."
Impact on Clinical Development
Dr. Chagin shared her own excitement about joining Context, highlighting the company’s innovative approach to T cell therapies and the potential these technologies have to significantly benefit patients suffering from solid tumors. She is looking forward to collaborating with the talented team at Context to build upon the strong groundwork already established and drive the next phase of clinical development for the company's promising therapies.
Stock Options and Inducement Grant
The appointment of Dr. Chagin comes along with a non-qualified stock option grant of 153,000 shares of the company's common stock as an inducement for her acceptance of the role. This stock option is tied to the closing price of the company's shares as recorded on Nasdaq on the first day of her employment and will vest in a structured manner over the upcoming years, contingent upon her continued employment and adherence to the terms outlined in the option agreement.
About Context Therapeutics
Context Therapeutics Inc. (NASDAQ: CNTX) is dedicated to developing T cell engaging bispecific antibodies aimed at combating solid tumors. The company is focused on creating a cutting-edge portfolio of T cell engaging therapeutics, including CTIM-76, a potent Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context's operations are based in Philadelphia, and further information can be found on their website or through their social media channels.
Frequently Asked Questions
Who is Dr. Karen Chagin?
Dr. Karen Chagin is the newly appointed Chief Medical Officer of Context Therapeutics, bringing over a decade of experience in T cell therapy.
When will Dr. Chagin officially start her role?
Dr. Chagin will officially assume her role as Chief Medical Officer on June 9, 2025.
What are some of Context's key therapeutic developments?
Context Therapeutics is developing T cell engaging bispecific antibodies, including promising candidates like CTIM-76 and CT-95.
How does Context Therapeutics plan to grow?
Under Dr. Chagin's leadership, Context aims to leverage her expertise to advance their clinical programs and expand their therapeutics portfolio.
Where is Context Therapeutics located?
Context Therapeutics is headquartered in Philadelphia, where it spearheads innovative biopharmaceutical advancements.
